Foghorn therapeutics to participate in the 41st cowen annual healthcare conference

Cambridge, mass., feb. 22, 2021 (globe newswire) -- foghorn therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that sam agresta, m.d., m.p.h, chief medical officer is scheduled to participate in a leukemias panel discussion at the cowen 41st annual healthcare conference at 11:40 a.m. et on march 3, 2021.
FHTX Ratings Summary
FHTX Quant Ranking